ArticlePostepy dermatologii i alergologii2025
Sensitivity of serum galactomannan antigen in the diagnosis of invasive aspergillosis in patients with obstructive pulmonary diseases (asthma and chronic obstructive pulmonary diseases).
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.American journal of respiratory and critical care medicine · 2026Article
- Article
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Invasive pulmonary aspergillosis in the post-COVID-19 era: diagnosis, treatment, and what lies ahead.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adverse clinical outcomes often result from the concomitant presence of invasive pulmonary aspergillosis (IPA) in patients with obstructive pulmonary diseases (asthma and chronic obstructive pulmonary diseases (COPD)). Aim: This work was developed to assess the risk factors (RFs) for patients with concurrent IPA and the diagnostic sensitivity of existing detection methods. Material and methods: This was a case control study on patients with acute exacerbation of obstructive pulmonary diseases (OPD) hospitalized from January 2022 to December 2023; patients were categorized into an IPA group ( Results: Prolonged use of BSAs (≥ 2 weeks) and corticosteroids (≥ 3 weeks), along with low albumin levels emerged as independent RFs for concurrent IPA. The sensitivity of GM antigen detection (64.1%) was the highest among the three methods, with specificity slightly lower than IgG detection (75.68%, 81.08%), yet still not reaching the ideal level. Conclusions: Risk assessment for asthma and COPD patients with concurrent IPA should encompass an evaluation of prolonged antibiotic and steroid use, along with a comprehensive consideration of nutritional and immune status. Current IPA detection methods should be evaluated in conjunction with clinical conditions to enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.